Phase II Study: Neoadjuvant Gemcitabine, Docetaxel and Capecitabine Followed by Neoadjuvant Radiation Therapy With Gemcitabine and Capecitabine in the Treatment of Stage II and III Pancreatic Adenocarcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT01065870

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:35:33.563063+00:00

Published At

2014-01-29T00:00:00+00:00

Record Updated At

2014-01-29

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Pancreatic Cancer Stage II", "Pancreatic Cancer Stage III"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2014-01-29"

protocolSection.identificationModule.nctId

"NCT01065870"

protocolSection.identificationModule.officialTitle

"Phase II Study: Neoadjuvant Gemcitabine, Docetaxel and Capecitabine Followed by Neoadjuvant Radiation Therapy With Gemcitabine and Capecitabine in the Treatment of Stage II and III Pancreatic Adenocarcinoma"

protocolSection.statusModule.overallStatus

"UNKNOWN"

protocolSection.designModule.phases

["PHASE2", "PHASE3"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Pancreatic Cancer Stage II (protocolSection.conditionsModule.conditions)
• Pancreatic Cancer Stage III (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.